| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C32H42N6O3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. It can be used for epitranscriptomic modulation of cellular processes and has antitumor activity, and it can also be used as a chemical probe for studying METTL3[1]. It is supplied as an off-white to light yellow solid (C32H42N6O3, MW 558.71) at 99.90% purity.
Physical & Chemical Properties
| CAS Number | 2813577-78-3 |
|---|---|
| Molecular Formula | C32H42N6O3 |
| Molecular Weight | 558.71 g/mol |
| Purity | 99.90% |
| Appearance | Solid |
| Color | Off-white to light yellow |
| SMILES | O=C(NC[C@@]1(O)CN(C2=NC=NC(NCC3=CC=CC=C3)=C2)CCC1)C4=CC=C(CN5CCC(C)(C)CC5)C=C4O |
| Signaling Pathway | Apoptosis |
| Solubility | In Vitro: DMSO: 80 mg/mL (143.19 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 280 nM (METTL3)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Moroz-Omori EV, et al. METTL3 inhibitors for epitranscriptomic modulation of cellular processes. bioRxiv. 2020 Oct 13.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 80 mg/mL (143.19 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 6 mg/mL (10.74 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 6 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (60.0 mg/mL) to 900 μL corn oil. |
Protocol 2
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 5.5 mg/mL (9.84 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 5.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (55.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 3
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 5.5 mg/mL (9.84 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 5.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (55.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
UZH1a (2.5-160 μM; 72 h) inhibits growth of MOLM-13, HEK293T, and U2Os cells; the IC50s are 11 μM, 67 μM, and 87 μM, respectively[1]. UZH1a (2.5-100 μM; 16 h) dose-dependently lowers the m6A methylation level of mRNA from MOLM-13 cells (IC50=4.6 μM)[1]. UZH1a (40 μM; 16 h) decreases m6A methylation in mRNA from MOLM-13, HEK293T, and U2Os cells[1]. In MOLM-13 cells, UZH1a (20 μM; 16 h) increases apoptosis and causes cell cycle arrest[1].
Cell Viability Assay[1]
| Cell Line | MOLM-13, HEK293T, and U2Os cells |
|---|---|
| Concentration | 2.5-160 μM |
| Incubation Time | 72 hours |
| Result | Inhibited the growth of MOLM-13, HEK293T, and U2Os cells in a dose-dependent manner. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
EBV Exploits RNA m6A Modification to Promote Cell Survival and Progeny Virus Production During Lytic Cycle. Front Microbiol 2022 Jun 15;13:870816. PMID: 35783391
Epitranscriptomic m6A modifications during reactivation of HIV-1 latency in CD4+ T cells. mBio 2024 Nov 13;15(11):e0221424. PMID: 39373537
METTL3 drives malignant progression in TP53-mutant prostate cancer. Mol Biol Rep 2025 Nov 11;53(1):66. PMID: 41217561
